Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer

12 Nov 2024

Abstract excerpt

Treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, the most common type of breast cancer, has faced challenges such as endocrine therapy resistance and distant relapse. Immunotherapy has shown progress in treating triple-negative breast cancer, but immunological research on HR+/HER2- breast cancer is still in its early stages. Here, we performed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Melanoma and MAPK Pathways
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39531335
DOI: 10.1172/jci183656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancerPMID 39531335Read ↗

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast CancerSemantic proximity Read ↗

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.Semantic proximity Read ↗

PSME2 identifies immune-hot tumors in breast cancer and associates with well therapeutic response to immunotherapySemantic proximity Read ↗

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancerSemantic proximity Read ↗

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read ↗

Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.Semantic proximity Read ↗

Clustering of HR+/HER2- breast cancer in an Asian cohort is driven by immune phenotypesSemantic proximity Read ↗

Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.Semantic proximity Read ↗

Heterogeneity of the tumor immune microenvironment and its clinical relevanceSemantic proximity Read ↗

Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancersSemantic proximity Read ↗

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer SubtypesSemantic proximity Read ↗

Multiomic dissection of HR <sup>+</sup> /HER2 <sup>−</sup> invasive lobular breast carcinoma reveals mobilized yet dysfunctional anti-tumor immunity shaped by tumor-stroma crosstalk and impaired antigen presentationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.